Sanofi

Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS

Retrieved on: 
Thursday, February 15, 2024
Week, Railway Workers' Union (Austria), Headache, Consortium, Multiple sclerosis, Sanofi, COVID-19, AFL, Patient, Plasma, Medical imaging

Findings also showed both doses of frexalimab provided significant reduction in new or enlarging T2 lesions, a secondary endpoint of the study.

Key Points: 
  • Findings also showed both doses of frexalimab provided significant reduction in new or enlarging T2 lesions, a secondary endpoint of the study.
  • Frexalimab is Sanofi’s novel second-generation investigational anti-CD40L antibody that has a unique method of action with the potential to address both acute and chronic neuroinflammation in MS without causing lymphocyte depletion.
  • “These published Phase 2 results for frexalimab represent important data in not only the potential treatment of MS but to the broader MS community.
  • Sanofi has initiated Phase 3 clinical trials of frexalimab in relapsing MS and non-relapsing secondary progressive MS.

Areteia Therapeutics Announces Additional $75MM in Series A Financing for Oral Dexpramipexole in Eosinophilic Asthma

Retrieved on: 
Tuesday, February 13, 2024
Biotechnology, Pharmaceutical, Health, Maverick Capital, Sanofi, Asthma, Therapy, ARCH Venture Partners, GV, Viking Global Investors, Pharmaceutical industry

Areteia Therapeutics, Inc. (“Areteia”) today announced $75 million in additional Series A financing to support expansion of the current Phase III development program of dexpramipexole in eosinophilic asthma, bringing total Series A funding to $425 million.

Key Points: 
  • Areteia Therapeutics, Inc. (“Areteia”) today announced $75 million in additional Series A financing to support expansion of the current Phase III development program of dexpramipexole in eosinophilic asthma, bringing total Series A funding to $425 million.
  • “We are delighted that leading biotech investors like Viking Global Investors and Marshall Wace have joined the syndicate.
  • Their investment in Areteia further deepens our already strong capitalization position,” said Jorge Bartolome, President and Chief Executive Officer of Areteia.
  • “We are pleased with the strong demand in this investment expansion round as our phase III program in eosinophilic asthma continues to make excellent progress.”

FADEL Issues Trading Update Indicating Strong FY23 Results with YOY Revenues Up 10%

Retrieved on: 
Wednesday, February 7, 2024
Hachette (publisher), FADEL, Sanofi, PepsiCo, Cross, IPO, Kimberly-Clark, Média-Participations, London Stock Exchange, Philip Morris, Retail

NEW YORK, Feb. 7, 2024 /PRNewswire-PRWeb/ -- FADEL®, innovator of brand compliance and rights and royalty management software, has announced its pre-close 2023 fiscal year trading update based on unaudited management accounts, with year-on-year revenue up 10% and recurring revenue up 31%. Further, prudent management of costs should ensure FADEL reaches EBITDA breakeven earlier than previously forecast.

Key Points: 
  • Further, prudent management of costs should ensure FADEL reaches EBITDA breakeven earlier than previously forecast.
  • 2023 brought big wins for FADEL in the consumer goods industry, with powerhouse net-new clients including PepsiCo, Kimberly-Clark, Sanofi, and Philip Morris.
  • These successes further solidify FADEL's position as an industry leader, providing a strong platform for future opportunities.
  • FADEL's significant incline in recurring revenue, encouraging pipeline, and upcoming professional services engagements, underpin confidence in revenue growth plans for 2024.

Experienced Life Sciences Leader Joins IPS as Regional Director to Lead New Australian Office

Retrieved on: 
Tuesday, February 6, 2024
Consulting, Biotechnology, Manufacturing, Construction & Property, Professional Services, Other Health, Health, Pharmaceutical, Architecture, Engineering, Other Construction & Property, Growth, IPS, ANZ, Cell, Research, Sanofi, Patient, AstraZeneca, Gene, GSK

IPS-Integrated Project Services, LLC , a leading provider of engineering , procurement , construction management , and validation (EPCMV) services, proudly announces the appointment of Gordon Nicholson as the Regional Director, ANZ (Australia, New Zealand), to lead IPS’ new Melbourne, Australia office.

Key Points: 
  • IPS-Integrated Project Services, LLC , a leading provider of engineering , procurement , construction management , and validation (EPCMV) services, proudly announces the appointment of Gordon Nicholson as the Regional Director, ANZ (Australia, New Zealand), to lead IPS’ new Melbourne, Australia office.
  • Before joining IPS, Gordon served in leadership roles across the APAC region from Singapore to Shanghai and Melbourne.
  • “Gordon’s appointment as Regional Director, ANZ allows us to further support our clients in bringing life-changing therapies to patients in Australia and beyond,” said Matthew Shippey, Managing Director, APAC.
  • Gordon’s leadership will be instrumental in fostering growth within the Australian market, positioning the company as a leading force in the life sciences and pharmaceutical manufacturing sectors.

Medidata and Sanofi Vaccines Extend Collaboration to Improve Patient Centricity and Trial Efficiency

Retrieved on: 
Tuesday, February 6, 2024
Health, Health Technology, Practice Management, Clinical Trials, Pharmaceutical, Biotechnology, Cloud, Aircraft pilot, Clinical trial, Caregiver, Sanofi, Patient, Physician, Vaccine, Dassault Group, American Opportunity Tax Credit, Pharmaceutical industry

Medidata , a Dassault Systèmes company and leading provider of clinical trial solutions to the life sciences industry, and Sanofi Vaccines, today announced a collaboration to harness Medidata eCOA to deploy in vaccine studies.

Key Points: 
  • Medidata , a Dassault Systèmes company and leading provider of clinical trial solutions to the life sciences industry, and Sanofi Vaccines, today announced a collaboration to harness Medidata eCOA to deploy in vaccine studies.
  • This builds on Medidata and Sanofi’s longstanding, successful experience using Medidata Rave EDC (electronic data capture).
  • The collaboration will use an eDiary function within eCOA to create an eDiary library specific to Sanofi’s vaccines.
  • “Expanding our collaboration with Medidata will enable us to improve our clinical development processes as we seek to deliver breakthrough vaccines to patients,” said the global head of clinical data management at Sanofi Vaccines.

Press Release: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline

Retrieved on: 
Thursday, February 1, 2024
EPS, Growth, AI, Sanofi, Patient, Immunology, CHC, Chronic obstructive pulmonary disease, CER

Applying average January 2024 exchange rates, the currency impact on 2024 business EPS is estimated between -3.5% to -4.5%.

Key Points: 
  • Applying average January 2024 exchange rates, the currency impact on 2024 business EPS is estimated between -3.5% to -4.5%.
  • “2023 marked a critical year on our journey to become a development-driven, tech-powered biopharma company committed to serving patients and accelerating growth.
  • We have delivered another year of strong underlying performance of our core drivers in Specialty Care and Vaccines supported by the outstanding launch execution of Beyfortus, Altuviiio and Tzield.
  • At the same time, we are taking steps to become a pure-play biopharma company with more than €10bn sales contribution from Pharma launches by 2030(4).”

MDB Capital Holdings Issues Annual Letter to Shareholders

Retrieved on: 
Wednesday, January 31, 2024
Partnering, Family, DTC, Season, Failure, Pacific Ocean, Public, MDBH, Sanofi, University, Athlete, Splenic infarction, FDA, MDB, Inflammation, Publication, Investment, Type 1, Entrepreneurship, Bloomberg, Physician, Insulin, IP, Culture, Letter, Fox Business, Holiday, Probability, Invention, Sales

Addison, TX, Jan. 31, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform with the objective of growing the public venture marketplace and optimizing the way meaningful technologies are financed and built, today released its annual letter to shareholders from its CEO and Co-Founder, Christopher Marlett.

Key Points: 
  • Addison, TX, Jan. 31, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform with the objective of growing the public venture marketplace and optimizing the way meaningful technologies are financed and built, today released its annual letter to shareholders from its CEO and Co-Founder, Christopher Marlett.
  • To the Shareholders of MDB Capital Holdings, LLC:
    Welcome to our first annual letter, which I plan to send every January to reflect on the past year and how what we learned will shape our plans for the following year.
  • Undervalued Public Companies: We identify and partner with more mature public companies with undervalued technologies that possess significant leadership potential.
  • We then combine that with our community of experienced investors that commit not only their monetary capital, but their intellectual capital to help each company succeed.

Abdera Therapeutics Expands Management Team and Board of Directors

Retrieved on: 
Tuesday, January 30, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Sanofi, Pfizer, Neoplasm, National Cancer Institute, Science, Law, Novartis, Gorilla, Carcinoma, DLL3, Genentech, National Institutes of Health, Food, Therapy, Acquisition, Rest, Bangladesh Technical Education Board, Hematology, Princeton University, Gilead Sciences, University, Cancer, Internal medicine, SCB-2019, Pharmaceutical industry

“We are thrilled to welcome Philippe and Eric to Abdera,” said Lori Lyons-Williams, president and chief executive officer.

Key Points: 
  • “We are thrilled to welcome Philippe and Eric to Abdera,” said Lori Lyons-Williams, president and chief executive officer.
  • I am excited to join the Abdera team and help build a differentiated pipeline.”
    Mr. Dobmeier is an executive and board member with more than 20 years of experience in the biotechnology industry.
  • He currently serves on the boards of Structure Therapeutics and Atara Therapeutics.
  • “I look forward to working with the rest of the board and leadership team as Abdera prepares to transition into a clinical-stage company and enter its next phase of growth.”

AQEMIA Boosts Series A Funding to €60M to Accelerate on its Proprietary Therapeutic Pipeline

Retrieved on: 
Tuesday, January 30, 2024
Software, Research, Other Health, Pharmaceutical, Data Management, Oncology, Technology, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Health, Other Science, Animal, Growth, Sanofi, Investment, History, Drug discovery, Pharmaceutical industry

After raising €30M last year, the tech-enabled drug discovery company today announced it has received an additional €30 million investment, which brings the Series A funding round to €60 million.

Key Points: 
  • After raising €30M last year, the tech-enabled drug discovery company today announced it has received an additional €30 million investment, which brings the Series A funding round to €60 million.
  • This investment in AQEMIA is being led by Wendel Growth and also includes commitments by the company’s long-standing partners: Bpifrance Large Venture, Eurazeo and Elaia.
  • AQEMIA will leverage this new funding to accelerate the growth of its wholly-owned pipeline of drug discovery projects and assets as well as further scale its proprietary GenAI and deep physics drug discovery platform.
  • As AQEMIA moves forward with this fundraise, it is poised to intensify its mission of reshaping the drug discovery landscape.

Policymakers, Patients, and Industry Join National Minority Quality Forum to Raise Alarm of Cancer Care Disparities in Minoritized Communities to White House Cancer Moonshot

Retrieved on: 
Wednesday, January 24, 2024
Legislation, City, Risk, Moonshot, Soil, Poverty, Groundwater, Health equity, Hazardous waste, Disease, MSN, Notifiable disease, Exact sciences, Atmosphere, Prevalence, African-American neighborhood, Public policy, MDHHS, Alaska Natives, Cancer cluster, Cancer Moonshot, Water, White, Council, Mortality, Patient, MD, RN, Partnership, Attention, American Indians, Breast cancer, Statistics, Sanofi, Pharmaceutical industry

NMQF Releases Report that 56% of People of Color Live in Carcinogenic Environments; Announce Public-Private Collaboration to Address Problem

Key Points: 
  • The report, entitled Cancer Moonshot, Public Policy, and Medically Underserved Cancer Care Communities, raises a national alarm about disparities in cancer risk, screening, prevalence, and mortality prevalent in medically underserved communities across the United States.
  • This proximity increases cancer risk for these communities, shedding light on an environmental justice issue that demands immediate attention.
  • This has led to later-stage diagnoses, hindering timely access to care and treatment for these communities.
  • We echo President Biden's call to action and emphasize that achieving the vision of the Cancer Moonshot requires urgent and sustained attention to cancer disparities.